Literature DB >> 30862723

Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors.

Patrick A Ott1,2,3,4, Catherine J Wu5,6,7,8.   

Abstract

Lack of tumor T-cell infiltration is a barrier to the efficacy of immune checkpoint inhibitors and other immunotherapies in patients with cancer. Because of their ability to activate and augment tumor-specific T cells, vaccines are an attractive approach to direct T-cell responses into the tumor. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30862723      PMCID： PMC7067230          DOI： 10.1158/2159-8290.CD-18-1357

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  44 in total

1.  Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors:  Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

2.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

Authors:  Derin B Keskin; Annabelle J Anandappa; Jing Sun; Itay Tirosh; Nathan D Mathewson; Shuqiang Li; Giacomo Oliveira; Anita Giobbie-Hurder; Kristen Felt; Evisa Gjini; Sachet A Shukla; Zhuting Hu; Letitia Li; Phuong M Le; Rosa L Allesøe; Alyssa R Richman; Monika S Kowalczyk; Sara Abdelrahman; Jack E Geduldig; Sarah Charbonneau; Kristine Pelton; J Bryan Iorgulescu; Liudmila Elagina; Wandi Zhang; Oriol Olive; Christine McCluskey; Lars R Olsen; Jonathan Stevens; William J Lane; Andres M Salazar; Heather Daley; Patrick Y Wen; E Antonio Chiocca; Maegan Harden; Niall J Lennon; Stacey Gabriel; Gad Getz; Eric S Lander; Aviv Regev; Jerome Ritz; Donna Neuberg; Scott J Rodig; Keith L Ligon; Mario L Suvà; Kai W Wucherpfennig; Nir Hacohen; Edward F Fritsch; Kenneth J Livak; Patrick A Ott; Catherine J Wu; David A Reardon
Journal:  Nature       Date:  2018-12-19       Impact factor: 49.962

3.  Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.

Authors:  Rajeev K Shrimali; Shamim Ahmad; Vivek Verma; Peng Zeng; Sudha Ananth; Pankaj Gaur; Rachel M Gittelman; Erik Yusko; Catherine Sanders; Harlan Robins; Scott A Hammond; John E Janik; Mikayel Mkrtichyan; Seema Gupta; Samir N Khleif
Journal:  Cancer Immunol Res       Date:  2017-09       Impact factor: 11.151

Review 4.  Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Authors:  Zhuting Hu; Patrick A Ott; Catherine J Wu
Journal:  Nat Rev Immunol       Date:  2017-12-11       Impact factor: 53.106

Review 5.  Engineered T cells: the promise and challenges of cancer immunotherapy.

Authors:  Andrew D Fesnak; Carl H June; Bruce L Levine
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

6.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

Authors:  Lena M Kranz; Mustafa Diken; Heinrich Haas; Sebastian Kreiter; Carmen Loquai; Kerstin C Reuter; Martin Meng; Daniel Fritz; Fulvia Vascotto; Hossam Hefesha; Christian Grunwitz; Mathias Vormehr; Yves Hüsemann; Abderraouf Selmi; Andreas N Kuhn; Janina Buck; Evelyna Derhovanessian; Richard Rae; Sebastian Attig; Jan Diekmann; Robert A Jabulowsky; Sandra Heesch; Jessica Hassel; Peter Langguth; Stephan Grabbe; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2016-06-01       Impact factor: 49.962

7.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Authors:  Ugur Sahin; Evelyna Derhovanessian; Matthias Miller; Björn-Philipp Kloke; Petra Simon; Martin Löwer; Valesca Bukur; Arbel D Tadmor; Ulrich Luxemburger; Barbara Schrörs; Tana Omokoko; Mathias Vormehr; Christian Albrecht; Anna Paruzynski; Andreas N Kuhn; Janina Buck; Sandra Heesch; Katharina H Schreeb; Felicitas Müller; Inga Ortseifer; Isabel Vogler; Eva Godehardt; Sebastian Attig; Richard Rae; Andrea Breitkreuz; Claudia Tolliver; Martin Suchan; Goran Martic; Alexander Hohberger; Patrick Sorn; Jan Diekmann; Janko Ciesla; Olga Waksmann; Alexandra-Kemmer Brück; Meike Witt; Martina Zillgen; Andree Rothermel; Barbara Kasemann; David Langer; Stefanie Bolte; Mustafa Diken; Sebastian Kreiter; Romina Nemecek; Christoffer Gebhardt; Stephan Grabbe; Christoph Höller; Jochen Utikal; Christoph Huber; Carmen Loquai; Özlem Türeci
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

Review 8.  Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.

Authors:  James Q Wang; Yogesh S Jeelall; Laura L Ferguson; Keisuke Horikawa
Journal:  Front Immunol       Date:  2014-07-31       Impact factor: 7.561

9.  Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.

Authors:  Yared Hailemichael; Zhimin Dai; Nina Jaffarzad; Yang Ye; Miguel A Medina; Xue-Fei Huang; Stephanie M Dorta-Estremera; Nathaniel R Greeley; Giovanni Nitti; Weiyi Peng; Chengwen Liu; Yanyan Lou; Zhiqiang Wang; Wencai Ma; Brian Rabinovich; Ryan T Sowell; Kimberly S Schluns; Richard E Davis; Patrick Hwu; Willem W Overwijk
Journal:  Nat Med       Date:  2013-03-03       Impact factor: 53.440

10.  In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity.

Authors:  Geoffrey M Lynn; Richard Laga; Patricia A Darrah; Andrew S Ishizuka; Alexandra J Balaci; Andrés E Dulcey; Michal Pechar; Robert Pola; Michael Y Gerner; Ayako Yamamoto; Connor R Buechler; Kylie M Quinn; Margery G Smelkinson; Ondrej Vanek; Ryan Cawood; Thomas Hills; Olga Vasalatiy; Kathrin Kastenmüller; Joseph R Francica; Lalisa Stutts; Janine K Tom; Keun Ah Ryu; Aaron P Esser-Kahn; Tomas Etrych; Kerry D Fisher; Leonard W Seymour; Robert A Seder
Journal:  Nat Biotechnol       Date:  2015-10-26       Impact factor: 54.908
View more
  17 in total

1.  Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.

Authors:  Daniel Shae; Jessalyn J Baljon; Mohamed Wehbe; Plamen P Christov; Kyle W Becker; Amrendra Kumar; Naveenchandra Suryadevara; Carcia S Carson; Christian R Palmer; Frances C Knight; Sebastian Joyce; John T Wilson
Journal:  ACS Nano       Date:  2020-07-31       Impact factor: 15.881

2.  Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control.

Authors:  Elena Tondini; Niels R M Reintjens; Giulia Castello; Tsolere Arakelian; Marjolein Isendoorn; Marcel Camps; Jana Vree; Gijs A van der Marel; Dmitri V Filippov; Jeroen D C Codee; Ferry Ossendorp
Journal:  NPJ Vaccines       Date:  2022-06-23       Impact factor: 9.399

3.  A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA.

Authors:  Carcia S Carson; Kyle W Becker; Kyle M Garland; Hayden M Pagendarm; Payton T Stone; Karan Arora; Lihong Wang-Bishop; Jessalyn J Baljon; Lorena D Cruz; Sebastian Joyce; John T Wilson
Journal:  J Control Release       Date:  2022-03-15       Impact factor: 11.467

4.  From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.

Authors:  Toni K Choueiri; Laurence Albiges; Michael B Atkins; Ziad Bakouny; Gennady Bratslavsky; David A Braun; Naomi B Haas; John B A G Haanen; A Ari Hakimi; Michael A S Jewett; Eric Jonasch; William G Kaelin; Payal Kapur; Chris Labaki; Bryan Lewis; David F McDermott; Sumanta K Pal; Kevin Pels; Susan Poteat; Thomas Powles; W Kimryn Rathmell; Brian I Rini; Sabina Signoretti; Nizar M Tannir; Robert G Uzzo; Hans J Hammers
Journal:  Clin Cancer Res       Date:  2022-03-01       Impact factor: 13.801

5.  An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission.

Authors:  Luca Biavati; Carol Ann Huff; Anna Ferguson; Amy Sidorski; M Amanda Stevens; Lakshmi Rudraraju; Cristina Zucchinetti; Syed Abbas Ali; Philip Imus; Christian B Gocke; Rachel M Gittelman; Sarah Johnson; Catherine Sanders; Marissa Vignali; Anita Gandhi; Xiaobu Ye; Kimberly A Noonan; Ivan Borrello
Journal:  Clin Cancer Res       Date:  2021-10-19       Impact factor: 13.801

Review 6.  Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.

Authors:  David A Braun; Ziad Bakouny; Laure Hirsch; Ronan Flippot; Eliezer M Van Allen; Catherine J Wu; Toni K Choueiri
Journal:  Nat Rev Clin Oncol       Date:  2021-01-12       Impact factor: 66.675

7.  The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.

Authors:  Marco Punta; Victoria A Jennings; Alan A Melcher; Stefano Lise
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

Review 8.  Vaccine Therapies for Cancer: Then and Now.

Authors:  Michael A Morse; William R Gwin; Duane A Mitchell
Journal:  Target Oncol       Date:  2021-01-29       Impact factor: 4.493

9.  Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.

Authors:  Milene Peterson; Sierra Nicole Murphy; John Lainson; Jian Zhang; Luhui Shen; Chris W Diehnelt; Stephen Albert Johnston
Journal:  BMC Immunol       Date:  2020-05-05       Impact factor: 3.615

10.  Microfluidic-prepared DOTAP nanoparticles induce strong T-cell responses in mice.

Authors:  Yasunari Haseda; Lisa Munakata; Jie Meng; Ryo Suzuki; Taiki Aoshi
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.